Arthritis care & research, 22 September 2020 Evolution of interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide for systemic sclerosis. Ciaffi J, van Leeuwen NM, Boonstra M, Kroft LJM, Schouffoer AA, Ninaber MK, Huizinga TWJ, de Vries-Bouwstra JK
Objectives
Hematopoietic stem cell transplantation (HSCT) and cyclophosphamide (CYC) are treatment options for progressive interstitial lung disease associated with systemic sclerosis (SSc-ILD). The aims of our retrospective observational study were to evaluate1) the evolution of SSc-ILD assessed by high-resolution computed tomography (HRCT) in SSc patients treated with HSCT. A group of patients treated with CYC was included as frame of reference; 2) how pulmonary function tests (PFTs) associate with HRCT findings; 3) which factors predict ILD reduction.